Alcon Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALCON
ALCON has fifty-eight approved drugs.
There are forty-six US patents protecting ALCON drugs. There is one tentative approval on ALCON drugs.
There are two hundred and forty-one patent family members on ALCON drugs in thirty-three countries and eighty-eight supplementary protection certificates in fifteen countries.
Summary for Alcon
| International Patents: | 241 |
| US Patents: | 46 |
| Tradenames: | 49 |
| Ingredients: | 41 |
| NDAs: | 58 |
| Patent Litigation for Alcon: | See patent lawsuits for Alcon |
| PTAB Cases with Alcon as patent owner: | See PTAB cases with Alcon as patent owner |
Drugs and US Patents for Alcon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 9,993,470 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Alcon | PANTOPAQUE | iophendylate | INJECTABLE;INJECTION | 005319-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | 10,857,096 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | 10,864,219 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | 11,872,318 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alcon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alcon Pharms Ltd | TRAVATAN | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021257-001 | Mar 16, 2001 | 6,011,062 | ⤷ Start Trial |
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | 10,882,840 | ⤷ Start Trial |
| Alcon Pharms Ltd | TRAVATAN | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021257-001 | Mar 16, 2001 | 5,631,287 | ⤷ Start Trial |
| Alcon Labs Inc | PATADAY TWICE DAILY RELIEF | olopatadine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020688-001 | Dec 18, 1996 | 4,871,865 | ⤷ Start Trial |
| Alcon Labs Inc | SIMBRINZA | brimonidine tartrate; brinzolamide | SUSPENSION/DROPS;OPHTHALMIC | 204251-001 | Apr 19, 2013 | 6,316,441 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALCON drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 0.03% | ➤ Subscribe | 2004-12-23 |
| ➤ Subscribe | Ophthalmic Solution | 0.00% | ➤ Subscribe | 2008-11-28 |
International Patents for Alcon Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2584858 | ⤷ Start Trial |
| Australia | 2018202074 | ⤷ Start Trial |
| China | 105534970 | ⤷ Start Trial |
| Poland | 2722035 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2010148190 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alcon Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2957286 | 132019000000021 | Italy | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM E QUALSIASI SUO SALE O DERIVATO(VELTASSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1179, 20170721 |
| 1514548 | C300671 | Netherlands | ⤷ Start Trial | PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128 |
| 3752510 | CR 2025 00041 | Denmark | ⤷ Start Trial | PRODUCT NAME: VANZACAFTOR ELLER ET FARMACEUTISK ACCEPTABLELT SALT DERAF, FORTRINSVIS ET CALCIUM-SALT DERAF; REG. NO/DATE: EU/1/25/1943 20250701 |
| 3053913 | 2020C/510 | Belgium | ⤷ Start Trial | PRODUCT NAME: RHOKIINSA - NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/19/1400 20191121 |
| 3752510 | 202540037 | Slovenia | ⤷ Start Trial | PRODUCT NAME: VANZACAFTOR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY A CALCIUM SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/25/1943; DATE OF NATIONAL AUTHORISATION: 20250630; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
